

Minimal Symptom Expression (MSE) with Active C1s Inhibition with Claseprubart

Poster #218



Marek Śmiłowski,¹ Nils Erik Gilhus,² Maria Ait-Tihyaty,³ Caitlin M Briggs,³ Uzma Siddiqui,³ Luke Hickey,³ Marianna Lalla,³ Said R Beydoun⁴

¹Neurologia Śląska Centrum Medyczne, Katowice, Poland; ²Haukeland University Hospital, Bergen, Norway; ³Dianthus Therapeutics, NY, USA; ⁴University of Southern California, CA, USA


MAIN FINDINGS

- 300mg claseprubart-treated patients were four times more likely to achieve MG-ADL-MSE and six times more likely to achieve QMG-MSE versus placebo.
- Achievement of MSE was rapid and all 300mg claseprubart-treated patients who achieved MG-ADL-MSE maintained a remission-like state for at least 6 weeks.
- The results of this analysis further support the clinical efficacy of claseprubart in patients with AChR Ab+ gMG with the potential benefit of infrequent subcutaneous self-administration.

INTRODUCTION

- Generalized myasthenia gravis (gMG) is an autoimmune disease caused by autoantibodies targeting the acetylcholine receptor (AChR), leading to activation of the classical complement pathway (CCP) and damage to the neuromuscular junction.¹
 - Patients with gMG experience a variety of physical symptoms related to muscle weakness throughout their lifetime, leading to lower quality of life compared to the general population.²
 - Achieving remission is an important goal and should be a key goal of any treatment for gMG.
- Claseprubart (DNTH103) is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the CCP by inhibiting only the active form of the C1s protein, a clinically validated complement target (Figure 1). Claseprubart is enhanced with YTE half-life extension technology designed to enable a more convenient subcutaneous, infrequently dosed, self-administered injection.
 - Current complement inhibitor therapies may be burdensome for patients and health care providers due to frequent and inconvenient administration.³⁻⁵

Figure 1. Claseprubart Mechanism of Action.



- The Phase 2 MaGic study in patients with gMG showed significant improvements in efficacy outcomes with subcutaneous (SC) claseprubart compared to placebo while maintaining a favorable safety profile.⁶
 - Here, we evaluated whether claseprubart use resulted in reaching minimal symptom expression (MSE), a measure of disease remission in gMG.⁷

OBJECTIVE

- To assess achievement of MSE in SC Q2W claseprubart-treated gMG patients in the MaGic study versus placebo.

METHODS


Study Design and Assessments

- MaGic is a global, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of SC claseprubart (NCT06282159).
- Adults aged 18–75 years (inclusive) with a diagnosis of AChR Ab+ gMG were randomized 1:1:1 to receive claseprubart 300mg (Q2W), claseprubart 600mg (Q2W), or placebo for 13 weeks, followed by an ongoing 52-week open-label extension and 40-week safety follow-up (Figure 2).
- The primary objective for the study was to evaluate the safety and tolerability of claseprubart. Key secondary efficacy assessments included change from baseline in the Myasthenia Gravis Activities of Daily Living (MG-ADL) Scale Score and the Quantitative Myasthenia Gravis (QMG) Scale score.

Minimal Symptom Expression Analysis

- MG-ADL-MSE was defined as achieving an MG-ADL score of 0 or 1.
- QMG-MSE was defined as achieving a QMG score of ≤ 3 .

Figure 2. MaGic Phase 2 Study Design.



RESULTS


Baseline Characteristics and Disposition

- Sixty-five patients with AChR Ab+ gMG were randomized and received 300mg SC claseprubart (n=21), 600mg SC claseprubart (n=22), or placebo (n=22). Demographics across treatment arms were generally well-balanced. Approximately 57% of patients in the study were male with a mean age of 54.8 (standard deviation 14.1) years and a median disease duration of 5.6 years.
- Sixty-three patients completed the 13-week randomized controlled portion of the study. One placebo and one 300mg claseprubart patient discontinued, neither due to an adverse event.

Improvement in MG-ADL and QMG Scores

- MG-ADL score was significantly improved with both dose groups of claseprubart compared to placebo at Week 13 (Figure 3A).
 - Improvement was observed as early as Week 1 in 300mg ($p=0.0908$ vs. placebo) and 600mg ($p=0.0211$) groups compared to placebo (one-sided p -values, $p<0.1$ considered nominally significant).
- Similarly, significant improvements in QMG score was observed in both claseprubart dose groups at Week 13 compared to placebo (Figure 3B).
 - Rapid improvement at Week 1 was observed with claseprubart (300mg [$p=0.0042$ vs. placebo]; 600mg [$p=0.0418$]) compared to placebo.


Figure 3. Change in MG-ADL and QMG score by Week.



Minimal Symptom Expression

- At Week 13, significantly more patients from the 300mg claseprubart arm (37% [7/19], adjusted odds ratio (OR) 3.81, $p=0.0550$ vs. placebo) achieved MG-ADL-MSE compared to 14% (3/22) of placebo-treated patients (Figure 4A).
 - Achievement of MG-ADL-MSE was rapid with 300mg claseprubart, beginning at Week 5 (OR 4.60, $p=0.0358$ vs. placebo).
 - Median time to achieve MG-ADL-MSE was 3 weeks with 300mg claseprubart.
 - Of the 300mg claseprubart-treated patients who achieved MG-ADL-MSE at Week 13, all demonstrated MSE for at least 6 consecutive weeks.
- QMG-MSE was achieved by significantly more 300mg claseprubart-treated patients at Week 13 (32% [6/19], OR 5.84, $p=0.0387$ vs. placebo) compared to placebo-treated patients (9% [2/22]) (Figure 4B).
 - Median time to achieve QMG-MSE was 3 weeks with 300mg claseprubart.
 - Of the 300mg claseprubart-treated patients who achieved QMG-MSE at Week 13, five of six patients demonstrated MSE for at least 6 consecutive weeks.

Figure 4. Minimal Symptom Expression.



References

- Howard J, et al. Ann New York Acad Sci 2017;1412:113–128
- Chou M, et al. Muscle & Nerve 2025;72:1035–1195
- SOLIRIS (eculizumab) Prescribing Information
- ULTOMIRIS (ravulizumab) Prescribing Information
- ZILBRYSP (zilucoplan) Prescribing Information
- Narayanaswami P. AANEM 2025
- Zhao R, et al. J Translat Med 2021;19:285

Acknowledgements

The authors thank Aji Nair of Dianthus Therapeutics Inc. for assistance with the preparation of this poster, and Eastmond Medicom Ltd for editing and production support, funded by Dianthus Therapeutics Inc.

Disclosures

MS, ENG and SRB have received grants, honoraria and/or consultancy fees from Dianthus. MAT, CMB, US, LH and ML are employees of Dianthus.